Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Guardant Health Q1 2026 Earnings Call - Revenue Surges 48% as Screening and Oncology Flywheel Accelerates
Guardant Health delivered a breakout first quarter, with revenue jumping 48% year-over-year to $302 million. The growth was broad-based, driven by a 47% surge in oncology test volumes and a massive ex...
- Total revenue surged 48% year-over-year to $302 million in Q1 2026, marking the fastest YoY growth rate in five years and pushing trailing twelve-month revenue past $1 billion.
- Oncology revenue grew 36% to $205 million, driven by a 47% increase in test volumes to approximately 86,000, with strong performance across Guardant360 Liquid, Tissue, and Reveal.
- Shield screening revenue exploded from $6 million to $42 million, fueled by a 44,000-test volume and a successful collaboration with Quest Diagnostics, which expanded market reach.
- +9 more takeaways
HubSpot Q1 2026 Earnings Call - AI Agents Drive Margin Expansion and Upmarket Growth
HubSpot delivered a resilient Q1 2026, posting 23% reported revenue growth and expanding non-GAAP operating margins by 400 basis points to 18%. The quarter was defined by a strategic pivot toward outc...
- Q1 2026 revenue grew 23% year-over-year on a reported basis and 18% in constant currency, driven by strong subscription and services growth.
- Non-GAAP operating margin expanded 400 basis points year-over-year to 18%, reflecting disciplined hiring and FX benefits.
- Total customer base reached nearly 300,000 globally, adding 10,800 net customers in the quarter.
- +7 more takeaways
Definium Therapeutics Q1 2026 Earnings Call - Three Phase III Readouts Loom
Definium Therapeutics is entering a high-stakes phase with three pivotal Phase III data readouts for its lead asset, DT120 ODT, scheduled for the second and third quarters of 2026. The company is adva...
- Definium Therapeutics is approaching a critical inflection point with three pivotal Phase III data readouts for DT120 ODT scheduled for Q2 and Q3 2026.
- The Emerge study in major depressive disorder (MDD) is complete with 149 participants and will report top-line data later this quarter.
- Two Phase III studies in generalized anxiety disorder (GAD), Voyage and Panorama, will report top-line data in Q3, with Panorama having exceeded its enrollment target.
- +7 more takeaways
Zymeworks Q1 2026 Earnings Call - Regulatory Catalysts and RAS ADC Pipeline Expansion
Zymeworks is approaching a critical inflection point with the August 25, 2026 PDUFA date for zanidatamab in first-line GEA and an sBLA filing in China. These milestones unlock $300 million in near-ter...
- The August 25, 2026 PDUFA date for zanidatamab in first-line GEA marks a pivotal near-term catalyst, with a $250 million milestone payment from Jazz upon U.S. approval.
- An sBLA filing has been submitted in China for first-line GEA, triggering a $50 million milestone payment from partner BeOne upon approval.
- Revenue fell to $2.4 million in Q1 2026 from $27.1 million in Q1 2025, driven by the absence of non-recurring clinical milestones from the prior year.
- +7 more takeaways
Akamai Technologies Q1 2026 Earnings Call - $1.8 Billion AI Infrastructure Win Signals Shift to Distributed Inference Grid
Akamai Technologies delivered a strong Q1 2026, driven by a record $1.8 billion seven-year cloud infrastructure deal with a frontier AI model company. This landmark contract, alongside a $200 million ...
- Akamai secured a historic $1.8 billion, seven-year cloud infrastructure services contract with a leading frontier AI model company, marking the largest deal in the firm’s history.
- Cloud Infrastructure Services (CIS) revenue surged 40% year-over-year to $95 million in Q1, reflecting rapid adoption of Akamai’s distributed AI inference platform.
- Total Q1 revenue reached $1.074 billion, up 6% year-over-year, with security revenue growing 11% and delivery revenue declining 7% due to the Edgio transaction.
- +7 more takeaways
Alta Equipment Group Q1 2026 Earnings Call - Q1 Weakness Masks Strong Booking Inflection and Margin Recovery
Alta Equipment Group reported a disappointing Q1 2026, with revenues falling 3% year-over-year to $410.5 million and adjusted EBITDA coming in at $28.1 million. The miss was driven by a perfect storm ...
- Q1 revenues fell 3% year-over-year to $410.5 million, with adjusted EBITDA of $28.1 million missing internal expectations due to seasonal headwinds and tax-driven pull-forward sales in Q4 2025.
- Material Handling segment revenues declined 4.7% to $150.5 million, driven by soft used equipment sales, but bookings surged to their strongest level since June 2023, signaling a clear inflection point.
- Construction Equipment revenues remained flat at $244.3 million, supported by strong quoting activity and fully funded state and federal infrastructure spending, despite a delayed start to the seasonal construction cycle.
- +7 more takeaways
Globus Medical Q1 2026 Earnings Call - Margin Expansion and EPS Guidance Hike
Globus Medical delivered a robust Q1 2026, with revenue rising 27% to $759.9 million and non-GAAP EPS jumping 64.7% to $1.12. The company is clearly executing on its integration and margin expansion p...
- Q1 2026 revenue reached $759.9 million, a 27% increase year-over-year, driven by strong performance across US Spine, International Spine, and Trauma.
- Non-GAAP EPS surged 64.7% to $1.12, beating expectations and prompting management to raise full-year EPS guidance to $4.70-$4.80.
- Adjusted gross profit margin remained resilient at 69.2% despite a typical seasonal Q1 decline, highlighting successful manufacturing and supply chain synergies.
- +7 more takeaways
Oportun Financial Corporation Q1 2026 Earnings Call - New CEO Reiterates Full-Year Guidance Amid Tight Credit Posture
Oportun Financial reported a cautious Q1 2026, marked by an 11% decline in originations and a 12.65% annualized net charge-off rate, the midpoint of guidance. The new CEO, Doug Bland, arrived less tha...
- New CEO Doug Bland, who joined less than three weeks ago, chose to reiterate the full-year 2026 guidance rather than announce a new strategy, citing the need for a deeper assessment of the business foundation.
- Originations declined 11% year-over-year in Q1, driven by seasonality and a strategic shift toward returning members, who now account for 79% of originations compared to 63% in the prior year quarter.
- The annualized net charge-off rate came in at 12.65%, the midpoint of guidance, but management expects this to be the highest rate of 2026, with delinquency rates improving sequentially.
- +10 more takeaways
Covista Q3 2026 Earnings Call - Chamberlain Returns to Growth, Guidance Raised Amid Structural Healthcare Labor Shortage
Covista delivered a strong third quarter, driven by enrollment momentum across Chamberlain, Walden, and its medical and veterinary segments. Chamberlain returned to positive total enrollment growth ah...
- Covista surpassed 100,000 total students with 11 consecutive quarters of growth, marking a structural inflection point in its national healthcare education platform.
- Chamberlain returned to positive total enrollment growth (0.5%) ahead of plan after fixing marketing effectiveness and funnel conversion issues, with application volumes and conversion rates normalizing to historical levels.
- Walden University set a new enrollment record with 12.3% growth to over 54,000 students, driven by broad-based program gains and improved first-to-second semester retention.
- +7 more takeaways
Inogen Q1 2026 Earnings Call - International Growth and Pipeline Expansion Offset U.S. Rental Pressure
Inogen delivered Q1 2026 revenue of $85.1 million, beating expectations as international sales surged 18% year-over-year, more than compensating for a 5% decline in U.S. sales. The company is navigati...
- Total revenue reached $85.1 million, up 3.4% year-over-year, beating management expectations.
- International sales surged 18% year-over-year to $37.7 million, driven by strong execution in Eastern Europe, Latin America, and Asia Pacific.
- U.S. sales declined 5% to $34.7 million, pressured by a structural shift where 60% of new long-term patients now start on POCs, hurting direct-to-consumer and rental channels.
- +10 more takeaways